Search

Displaying results 1781 - 1790 of 10000 in total
  1. Drug

    Ecamsule

    go.drugbank.com/drugs/DB09534
    Approved

    Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal.

    Mixtures: Thermal S Uv SPF 20, Thermal Fix Uv SPF 20
  2. Drug

    Tropicamide

    go.drugbank.com/drugs/DB00809
    Approved

    Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cyclop...

    Mixtures: MYDRIASERT 0,28 MG/5,4 MG GÖZ INSERTI ,20 INSERT, Mydrane 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml InjektionslösungProducts: Tropicamide 1% - Liq Oph 10mg/ml, MİDAX %1 GÖZ DAMLASI, ÇÖZELTİ, 5 ML
  3. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: ORALAIR 100 IR + 300 IR Sublingualtabletten, ORALAIR 100 IR + 300 IR SublingualtablettenCategories: Complex Mixtures
  4. Drug

    2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol

    go.drugbank.com/drugs/DB08773
    Experimental

    Synonyms: Raloxifene core
  5. Pathway

    2-Ketoglutarate Dehydrogenase Complex Deficiency

    smpdb.ca/view/SMP0125755
    Disease

    oxoglutarate dehydrogenase complex (OGDC). … 2-Ketoglutarate dehydrogenase complex deficiency, also known as alpha-ketoglutarate dehydrogenase deficiency or oxoglutaric aciduria, is an autosomal recessive disorder of the Krebs cycle caused by a defective

    Drugs: Pyruvic acid · Biotin · Succinic acid · NADH · ATP · Magnesium cation +4 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial
  6. Drug

    Nadroparin

    go.drugbank.com/drugs/DB08813
    ApprovedInvestigationalWithdrawn

    Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

    Mixtures: FRAXIPARINE 0.3 MLProducts: /ml Injektionslösung, FRAXIPARINE 1 ML
  7. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    Compared to human insulin, it has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. … This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin.

    Mixtures: RYZODEG 100 UNIDADES/ML, NOVOMIX 30 FLEXPEN INJECTION 100 u/mlProducts: 100 U/ML, FIASP® 100 UNIDADES/ML
  8. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors … Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471].

    Mixtures: COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  9. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.

  10. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.